Published in Glycobiology on August 08, 2014
Central Role of Metabolism in Endothelial Cell Function and Vascular Disease. Physiology (Bethesda) (2017) 0.75
Thrombospondin-1-Based Antiangiogenic Therapy. J Ocul Pharmacol Ther (2015) 0.75
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med (1994) 16.24
Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol (1994) 5.76
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest (2004) 5.59
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Vascular endothelial growth factor and angiogenesis. Pharmacol Rev (2004) 5.41
Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology (2013) 3.92
Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res (1998) 3.79
FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci (2001) 3.42
Corneal neovascularization. Curr Opin Ophthalmol (2001) 3.22
Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci (1996) 3.21
The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci (1995) 2.99
Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci (1996) 2.87
Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol (2008) 2.83
Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A (2006) 2.75
Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A (1996) 2.67
Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol (2002) 2.57
Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell (2014) 2.29
Regulation of alternative macrophage activation by galectin-3. J Immunol (2008) 2.28
Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A (2006) 2.26
NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol Biol Cell (2004) 2.14
Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med (2011) 2.09
Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol (2002) 2.01
Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst (2002) 1.98
Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol (2000) 1.97
Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol (2000) 1.93
Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol (2007) 1.90
Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol (1996) 1.90
Fibrosis and diseases of the eye. J Clin Invest (2007) 1.79
Integrins: the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol (2008) 1.75
The mouse cornea micropocket angiogenesis assay. Nat Protoc (2007) 1.74
Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci (2000) 1.71
Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol (2006) 1.69
The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One (2008) 1.68
Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J (2002) 1.64
Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem (2012) 1.63
Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene (2008) 1.60
Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. Am J Ophthalmol (2005) 1.59
VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun (2008) 1.59
Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis (2007) 1.56
The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J (2007) 1.49
VEGF in biological control. J Cell Biochem (2007) 1.48
Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med (2010) 1.41
Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol (1996) 1.35
A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol (2012) 1.33
Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci (2002) 1.26
The alpha-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth. Cancer Res (1995) 1.26
Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood (2007) 1.24
Ocular neovascularization: basic mechanisms and therapeutic advances. Surv Ophthalmol (2007) 1.23
Protein modification by O-linked GlcNAc reduces angiogenesis by inhibiting Akt activity in endothelial cells. Arterioscler Thromb Vasc Biol (2008) 1.22
Morphologic changes in age-related maculopathy. Microsc Res Tech (1997) 1.19
Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology (2012) 1.19
Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2002) 1.18
Mediators of ocular angiogenesis. J Genet (2009) 1.17
Roles of integrins in tumor angiogenesis and lymphangiogenesis. Lymphat Res Biol (2008) 1.16
Plasma concentration of pigment epithelium-derived factor in patients with diabetic retinopathy. J Clin Endocrinol Metab (2007) 1.16
Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. Lab Invest (1996) 1.16
Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis. Am J Pathol (2007) 1.16
Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci (2002) 1.16
Angiogenesis and ophthalmic disease. Angiogenesis (1999) 1.15
Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem (2011) 1.13
Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood (2005) 1.13
Human corneal epithelial basement membrane and integrin alterations in diabetes and diabetic retinopathy. J Histochem Cytochem (1998) 1.10
A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin (2011) 1.09
Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. Diabetes (2005) 1.08
Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. Am J Pathol (2000) 1.07
Retinal and choroidal microangiopathies: therapeutic opportunities. Microvasc Res (2007) 1.06
Integrins as "functional hubs" in the regulation of pathological angiogenesis. Semin Cancer Biol (2009) 1.05
Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer (2010) 1.05
Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor. Exp Eye Res (2004) 1.03
Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. Mol Pharmacol (2006) 1.03
Expression of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in corneal lymphangiogenesis. Exp Eye Res (2001) 1.00
Cloning and characterization of the 5'-flanking region of the rat neuron-specific Class III beta-tubulin gene. Gene (2002) 1.00
Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye. Graefes Arch Clin Exp Ophthalmol (2012) 1.00
Modulation of endothelial cell migration and angiogenesis: a novel function for the "tandem-repeat" lectin galectin-8. FASEB J (2010) 0.98
Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res (2007) 0.94
1-Deoxymannojirimycin inhibits capillary tube formation in vitro. Analysis of N-linked oligosaccharides in bovine capillary endothelial cells. J Biol Chem (1992) 0.94
Wound healing angiogenesis: indirect stimulation by basic fibroblast growth factor. J Trauma (1990) 0.92
Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy. Invest Ophthalmol Vis Sci (2009) 0.91
Corneal neovascularization: molecular events and therapeutic options. Recent Pat Inflamm Allergy Drug Discov (2009) 0.90
Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization. J Biol Chem (2011) 0.90
Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci (2003) 0.89
The role of integrin alpha5beta1 in the regulation of corneal neovascularization. Exp Eye Res (2007) 0.88
Retinal O-linked N-acetylglucosamine protein modifications: implications for postnatal retinal vascularization and the pathogenesis of diabetic retinopathy. Mol Vis (2013) 0.88
Molecular basis for MMP9 induction and disruption of epithelial cell-cell contacts by galectin-3. J Cell Sci (2014) 0.88
Expression of integrins and MMPs during alkaline-burn-induced corneal angiogenesis. Invest Ophthalmol Vis Sci (2002) 0.87
Galectin-3 accelerates M2 macrophage infiltration and angiogenesis in tumors. Am J Pathol (2013) 0.86
SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci (2006) 0.86
Anti-angiogenic effects of non-peptide integrin alphavbeta3 specific antagonist on laser-induced choroidal neovascularization in mice. Graefes Arch Clin Exp Ophthalmol (2008) 0.85
Galectin-3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from TGFβ1-induced macrophages. Cancer Med (2014) 0.85
Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac). Exp Eye Res (2011) 0.84
Review of ranibizumab trials for neovascular age-related macular degeneration. Semin Ophthalmol (2011) 0.84
Etiology and natural history of diabetic retinopathy: an overview. Am J Health Syst Pharm (2007) 0.83
Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering. J Ophthalmol (2014) 0.82
Angiogenesis in the caprine caruncles in non-pregnant and pregnant normal and swainsonine-treated does. Anat Rec (Hoboken) (2007) 0.82
Functional and morphological changes induced by tunicamycin in dividing and confluent endothelial cells. Exp Cell Res (1992) 0.81
VEGF-binding aptides and the inhibition of choroidal and retinal neovascularization. Biomaterials (2014) 0.80
Topical application of integrin antagonists inhibits proliferative retinopathy. Horm Metab Res (2001) 0.80
Quantification of angiogenesis due to basic fibroblast growth factor in a modified rabbit corneal model. Ophthalmic Res (1992) 0.77
Inhibition of corneal neovascularization by alpha(v)-integrin antagonists in the rat. Graefes Arch Clin Exp Ophthalmol (2000) 0.76